---
title: "Multimorbidity with tuberculosis in Kampala: prevalence, care gaps and impact on outcomes"
id: "medrxiv-1-multimorbidity-in-tuberculosis-and-its-impact-on-health-and-treatment-outcomes"
canonical_url: "https://medichelpline.com/clinical-feed/medrxiv-1-multimorbidity-in-tuberculosis-and-its-impact-on-health-and-treatment-outcomes"
content_type: "clinical_feed_article"
specialty: "Infectious Disease"
source_name: "medRxiv (Clinical Preprints)"
source_url: "https://www.medrxiv.org/content/10.64898/2026.10.06.26364927v1?rss=1"
published_at: "2026-10-08T12:00:00.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Multimorbidity with tuberculosis in Kampala: prevalence, care gaps and impact on outcomes
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/medrxiv-1-multimorbidity-in-tuberculosis-and-its-impact-on-health-and-treatment-outcomes
- **Specialty:** [Infectious Disease](https://medichelpline.com/clinical-feed/infectious-disease.md)
- **Primary Source:** medRxiv (Clinical Preprints)
- **Source URL:** [Original Journal Publication](https://www.medrxiv.org/content/10.64898/2026.10.06.26364927v1?rss=1)
- **Published At:** 2026-10-08T12:00:00.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
- This prospective cohort enrolled 254 adults (≥18 years) initiating anti‑TB therapy at four clinics in Kampala between June 2024 and June 2025 to evaluate **multimorbidity** (TB plus ≥2 long‑term conditions) and its effects on health and treatment outcomes. - **Multimorbidity** prevalence was 39.4% (95% CI 33.3–45.7%); only 22.4% of participants had TB with no co‑existing condition. - The most common long‑term conditions were **HIV** (44.1%), **undernutrition** (39.8%) and **depression** (16.1%). - Care cascade analyses identified important gaps: failures in screening and diagnosis for **HIV**, diabetes mellitus and mental health conditions, and gaps in treatment delivery for hypertension. - At enrolment, multimorbidity was associated with worse physiological status (higher **NEWS**; adjusted mean difference 0.88, 95% CI 0.36–1.42) and lower health‑related quality of life (HRQoL; adjusted mean difference −10.75, 95% CI −16.77 to −4.73). - Multimorbidity increased the risk of persistent sputum bacillary load at month 2 (positive **TB‑MBLA**) and was linked to a higher risk of an unsuccessful TB treatment outcome (adjusted risk difference 9.88%, 95% CI 2.59–17.17). - All deaths observed in the cohort occurred among participants with multimorbidity. - Authors conclude that multimorbidity affected two in five adults with TB in this cohort and was associated with worse baseline health and poorer TB outcomes, arguing that **National TB programmes** are well placed to identify and manage co‑existing LTCs but must address condition‑specific gaps with tailored integrated care approaches. - Data are held under restricted access by the Infectious Diseases Institute, Makerere University; analysis code will be made available on GitHub per the source.
## Clinical Analysis & Structured Key Points
[](https://www.medrxiv.org/cdn-cgi/content?id=5v2T5YsidT5HAemFRSWrdDA55M.bU8rHU.66rZ0UBfg-1791506485.8861172-1.2.1.1-yY7NlLO9VlpXsU4iXyBSEt83TR3Caa43cSdu7KEVEYxOvE.PNWHcJqivJAnlaDGG) [Skip to main content](https://www.medrxiv.org/content/10.64898/2026.10.06.26364927v1?rss=1#main-content) [![medRxiv](https://www.medrxiv.org/sites/default/files/medrxiv_inner_logo.png)](https://www.medrxiv.org/) * [Home](https://www.medrxiv.org/) * [Submit](https://www.medrxiv.org/submit-a-manuscript) * [FAQ](https://www.medrxiv.org/about/FAQ) * [Blog](https://connect.medrxiv.org/news/) * [ALERTS / RSS](https://www.medrxiv.org/content/alertsrss) * [Resources](https://connect.medrxiv.org/resources/) * [About](https://www.medrxiv.org/content/about-medrxiv) Search for this keyword [Advanced Search](https://www.medrxiv.org/search) Follow this preprint # Multimorbidity in tuberculosis and its impact on health and treatment outcomes: A prospective cohort study [ View ORCID Profile](http://orcid.org/0009-0002-1894-3077)Katherine Hill, Lucy Alinaitwe, Florence Aber, Patricia Nerima, Paul Mubiri, Noela Clara Owarwo, Rogers Owori, Ronald Izati, Wilber Sabiiti, Natasha Walbaum, Molly Naisanga, Stellah Mpagama, Sarah Elizabeth Ellen Mills, Helen Ruth Stagg, Derek James Sloan, Christine Sekaggya-Wiltshire doi: https://doi.org/10.64898/2026.10.06.26364927 [This article is a preprint and has not been certified by peer review [](https://www.medrxiv.org/about/FAQ#unrefereed)[what does this mean?](https://www.medrxiv.org/about/FAQ#unrefereed)]. It reports new medical research that has yet to be evaluated and so should _not_ be used to guide clinical practice. Katherine Hill 1 University of St Andrews School of Medicine; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Katherine%2BHill%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Hill%20K&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AKatherine%2BHill%2B) * [ORCID record for Katherine Hill](http://orcid.org/0009-0002-1894-3077 "Open in new tab") * For correspondence: kh280@st-andrews.ac.uk Lucy Alinaitwe 2 Makerere University Infectious Diseases Institute; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Lucy%2BAlinaitwe%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Alinaitwe%20L&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3ALucy%2BAlinaitwe%2B) Florence Aber 2 Makerere University Infectious Diseases Institute; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Florence%2BAber%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Aber%20F&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AFlorence%2BAber%2B) Patricia Nerima 2 Makerere University Infectious Diseases Institute; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Patricia%2BNerima%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Nerima%20P&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3APatricia%2BNerima%2B) Paul Mubiri 2 Makerere University Infectious Diseases Institute; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Paul%2BMubiri%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Mubiri%20P&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3APaul%2BMubiri%2B) Noela Clara Owarwo 2 Makerere University Infectious Diseases Institute; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Noela%2B%2BClara%2BOwarwo%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Owarwo%20N&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3ANoela%2B%2BClara%2BOwarwo%2B) Rogers Owori 2 Makerere University Infectious Diseases Institute; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Rogers%2BOwori%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Owori%20R&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3ARogers%2BOwori%2B) Ronald Izati 3 Makerere University College of Health Sciences; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Ronald%2BIzati%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Izati%20R&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3ARonald%2BIzati%2B) Wilber Sabiiti 1 University of St Andrews School of Medicine; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Wilber%2BSabiiti%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Sabiiti%20W&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AWilber%2BSabiiti%2B) Natasha Walbaum 1 University of St Andrews School of Medicine; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Natasha%2BWalbaum%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Walbaum%20N&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3ANatasha%2BWalbaum%2B) Molly Naisanga 4 Gulu University Faculty of Medicine; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Molly%2BNaisanga%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Naisanga%20M&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AMolly%2BNaisanga%2B) Stellah Mpagama 5 Kibong'oto Infectious Diseases Hospital; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Stellah%2BMpagama%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Mpagama%20S&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AStellah%2BMpagama%2B) Sarah Elizabeth Ellen Mills 1 University of St Andrews School of Medicine; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Sarah%2B%2BElizabeth%2BEllen%2BMills%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Ellen%20Mills%20S&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3ASarah%2B%2BElizabeth%2BEllen%2BMills%2B) Helen Ruth Stagg 6 London School of Hygiene & Tropical Medicine * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Helen%2B%2BRuth%2BStagg%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Stagg%20H&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AHelen%2B%2BRuth%2BStagg%2B) Derek James Sloan 1 University of St Andrews School of Medicine; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Derek%2B%2BJames%2BSloan%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Sloan%20D&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3ADerek%2B%2BJames%2BSloan%2B) Christine Sekaggya-Wiltshire 2 Makerere University Infectious Diseases Institute; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Christine%2BSekaggya-Wiltshire%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Sekaggya-Wiltshire%20C&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AChristine%2BSekaggya-Wiltshire%2B) * [Abstract](https://www.medrxiv.org/content/10.64898/2026.10.06.26364927v1)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_art/node:1317105/1) * [Info/History](https://www.medrxiv.org/content/10.64898/2026.10.06.26364927v1.article-info)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_info/node:1317105/1) * [Metrics](https://www.medrxiv.org/content/10.64898/2026.10.06.26364927v1.article-metrics)[](https://www.medrxiv.org/panels_ajax_tab/article_tab_metrics/node:1317105/1) * [Data/Code](https://www.medrxiv.org/content/10.64898/2026.10.06.26364927v1.external-links)[](https://www.medrxiv.org/panels_ajax_tab/article_tab_data_code/node:1317105/1) * [ Preview PDF](https://www.medrxiv.org/content/10.64898/2026.10.06.26364927v1.full.pdf+html)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_pdf/node:1317105/1) ![Loading](https://www.medrxiv.org/sites/all/modules/contrib/panels_ajax_tab/images/loading.gif) ## Abstract Multimorbidity - the co-existence of two or more long-term health conditions (LTCs) - is increasingly common in low- and middle-income countries. Yet, in the African region, its prevalence in people with tuberculosis (TB) and its impact on treatment outcomes remain poorly characterised. We sought to determine the prevalence and patterns of multimorbidity and its impact on health and treatment outcomes in people with TB in Kampala, Uganda, and to evaluate cascades of care for hypertension, diabetes mellitus, HIV and mental health conditions. This was a prospective cohort study of adults (≥18 years) commencing anti-TB treatment at four clinics in Kampala between June 2024–June 2025. LTCs were identified through self-report, validated screening tools, clinical examination and blood analysis, using definitions informed by the Ho et al. Delphi consensus. Multimorbidity was defined as TB plus two or more LTCs. Participants were followed to month six to assess health-related quality of life (HRQoL), physiological status (National Early Warning Score (NEWS)), sputum bacillary clearance (TB-Molecular Bacterial Load Assay (TB-MBLA)) and WHO-defined treatment outcomes. Descriptive statistics were used to examine the prevalence and patterns of multimorbidity and evaluate cascades of care. The effect of multimorbidity on health and treatment outcomes was assessed using regression models. Among 254 adults with TB, the prevalence of multimorbidity was 39.4% (95% CI 33.3–45.7%); only 22.4% had TB with no co-existing condition. The most prevalent LTCs were HIV (44.1%), undernutrition (39.8%) and depression (16.1%). Care cascades revealed substantial gaps in screening and diagnosis (HIV, diabetes mellitus and mental health conditions) and treatment (hypertension). At enrolment, multimorbidity was associated with worse NEWS (adjusted mean difference 0.88, 95% CI 0.36 to 1.42) and HRQoL (adjusted mean difference in HRQoL score −10.75, 95% CI −16.77 to −4.73). Multimorbidity was associated with a higher risk of a positive sputum TB-MBLA at month 2 and a higher risk of an unsuccessful TB treatment outcome (adjusted risk difference 9.88%, 95% CI 2.59 to 17.17). All deaths occurred among participants with multimorbidity. Multimorbidity affected two in five adults with TB in this cohort and was associated with worse health at diagnosis and poorer treatment outcomes. National TB programmes are well placed to identify and manage co-existing LTCs, but care cascades show gaps at different stages for different conditions, underscoring the need for tailored, integrated approaches. ### Competing Interest Statement The authors have declared no competing interest. ### Clinical Protocols ### Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: University of St Andrews School of Medicine Ethics Committee Infectious Diseases Institute Research Ethics Committee Uganda National Council of Science and Technology I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable. Yes ## Data Availability The data underlying this study contain sensitive health information, including HIV status and mental health conditions, collected from a small cohort at identifiable clinic sites. Participants could potentially be re-identified, so the data cannot be shared publicly. Under the study's data management agreement, pseudo-anonymised data are held by the Infectious Diseases Institute (IDI), Makerere University, as data controller. Researchers who meet the criteria for access to confidential data can request it through IDI's established Standard Operating Procedures for data access, by contacting IDI's research department: research{at}idi.co.ug. Analysis code will be made available on publication at GitHub (https://github.com/khill280/MITICare-analysis.git) Copyright The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](http://creativecommons.org/licenses/by/4.0/). bioRxiv and medRxiv thank the following for their generous financial support: > The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, The University of Edinburgh, University of Washington, and Vrije Universiteit Amsterdam. [Donate to openRxiv ](https://www.zeffy.com/en-US/donation-form/donate-to-make-a-difference-10981) [ Back to top](https://www.medrxiv.org/content/10.64898/2026.10.06.26364927v1?rss=1#page) [ Previous](https://www.medrxiv.org/content/10.64898/2026.10.05.26363336v1 "Testing Bidirectional Genetic Links Between ADHD and the Big Five Personality Traits")[Next ](https://www.medrxiv.org/content/10.64898/2026.10.06.26364867v1 "Inflammation-Related Biomarkers Linking Environmental Chemical Mixtures and Metabolic Dysfunction-Associated Steatotic Liver Disease: A Population-Based Study from NHANES 1999-2020") Posted October 08, 2026. [ Download PDF](https://www.medrxiv.org/content/10.64898/2026.10.06.26364927v1.full.pdf) Print/Save Options [Download PDF](https://www.medrxiv.org/content/medrxiv/early/2026/10/08/2026.10.06.26364927.full.pdf)Full Text & In-line FiguresXML [More Info](https://www.medrxiv.org/about/FAQ#PrintOptions "More Information on Print/Save Options") [ Author Declarations](https://www.medrxiv.org/content/10.64898/2026.10.06.26364927v1#p-5) [ Data/Code](https://www.medrxiv.org/content/early/2026/10/08/2026.10.06.26364927.external-links) [ Email](https://www.medrxiv.org/ "Email this Article") [ Share](https://www.medrxiv.org/) Multimorbidity in tuberculosis and its impact on health and treatment outcomes: A prospective cohort study Katherine Hill, Lucy Alinaitwe, Florence Aber, Patricia Nerima, Paul Mubiri, Noela Clara Owarwo, Rogers Owori, Ronald Izati, Wilber Sabiiti, Natasha Walbaum, Molly Naisanga, Stellah Mpagama, Sarah Elizabeth Ellen Mills, Helen Ruth Stagg, Derek James Sloan, Christine Sekaggya-Wiltshire medRxiv 2026.10.06.26364927; doi: https://doi.org/10.64898/2026.10.06.26364927 [This article is a preprint and has not been certified by peer review [](https://www.medrxiv.org/about/FAQ#unrefereed)[what does this mean?](https://www.medrxiv.org/about/FAQ#unrefereed)]. It reports new medical research that has yet to be evaluated and so should _not_ be used to guide clinical practice. Share This Article: Copy [![Twitter logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/twitter.png)](https://www.medrxiv.org/highwire_log/share/twitter?link=http%3A%2F%2Ftwitter.com%2Fshare%3Furl%3Dhttps%253A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.64898%2F2026.10.06.26364927v1%26text%3DMultimorbidity%2520in%2520tuberculosis%2520and%2520its%2520impact%2520on%2520health%2520and%2520treatment%2520outcomes%253A%2520A%2520prospective%2520cohort%2520study "Share this on Twitter") [![Facebook logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/fb-blue.png)](https://www.medrxiv.org/highwire_log/share/facebook?link=http%3A%2F%2Fwww.facebook.com%2Fsharer.php%3Fu%3Dhttps%253A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.64898%2F2026.10.06.26364927v1%26t%3DMultimorbidity%2520in%2520tuberculosis%2520and%2520its%2520impact%2520on%2520health%2520and%2520treatment%2520outcomes%253A%2520A%2520prospective%2520cohort%2520study "Share on Facebook") [![LinkedIn logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/linkedin-32px.png)](https://www.medrxiv.org/highwire_log/share/linkedin?link=http%3A%2F%2Fwww.linkedin.com%2FshareArticle%3Fmini%3Dtrue%26url%3Dhttps%253A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.64898%2F2026.10.06.26364927v1%26title%3DMultimorbidity%2520in%2520tuberculosis%2520and%2520its%2520impact%2520on%2520health%2520and%2520treatment%2520outcomes%253A%2520A%2
## Related Clinical Research

- [Bupropion Hydrochloride for Improving Recovery in Acute Ischaemic Stroke: BASE Trial Protocol](https://medichelpline.com/clinical-feed/bmj-open-4-protocol-for-base-a-multicentre-double-blind-randomised-controlled-trial-of.md)
- [Determinants of Favorable MDR-TB Treatment Outcomes in Zambia, 2018–2022](https://medichelpline.com/clinical-feed/plos-one-16-determinants-of-favorable-treatment-outcomes-in-multidrug-resistant.md)
- [Mortality and Predictors Among People Living with HIV Newly Enrolled in Care at Bamenda Regional H](https://medichelpline.com/clinical-feed/medrxiv-11-mortality-and-associated-factors-among-people-living-with-hiv-newly-initiated.md)
- [Diet and Alzheimer’s risk: Why no single best diet fits everyone](https://medichelpline.com/clinical-feed/medical-news-today-0-is-there-a-best-diet-to-help-lower-alzheimer-s-risk.md)
- [Avoiding smoking, diabetes, and high blood pressure in midlife may add up to 13 dementia-free years](https://medichelpline.com/clinical-feed/medical-news-today-0-avoiding-3-risk-factors-in-midlife-could-add-13-dementia-free-years.md)

## Navigation
- [← Back to Infectious Disease Feed](https://medichelpline.com/clinical-feed/infectious-disease.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.